Compare Lucid Group Inc (LCID) vs Mesoblast Limited (MESO) Price & Performance

Lucid Group (LCID) trades at $3.82, down 1.8% on the day, with a bearish technical signal and weak fundamentals. The company reported a net loss of $2.70 billion in 2025, with negative gross and net income margins, and has missed earnings expectations for three consecutive quarters. Recent news highlights cost-saving initiatives and autonomous vehicle partnerships, but also delays in the Cosmos SUV launch and concerns over cash burn.

The outlook remains challenging due to persistent losses and high cash burn, though analyst consensus suggests potential upside with a $7.60 price target. Key risks include execution delays, competitive pressures, and the need for additional financing. Investor sentiment is cautious, with most analysts rating the stock Hold.

MESO trades at $14.29, up 2.51% today, amid bearish technical signals but positive fundamental developments. The stock shows strong revenue growth with FY2026 reaching $120 million, though profitability remains negative. Recent FDA approval for Ryoncil's potency assay and completion of Phase 3 back pain trials provide catalysts. Technical indicators show oversold conditions with RSI at 22.4, while moving averages signal bearish momentum.

Investment outlook balances high growth potential against persistent losses. The expanding Ryoncil market share and pipeline progress offer upside, but negative margins and cash burn pose risks. Analyst consensus leans bullish with 45% buy ratings, yet the stock faces execution challenges in achieving profitability amid competitive pressures.